MedTrace Logo

Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)

NCT02624830 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-02-12

No results posted yet for this study

Summary

The purpose of this study is to investigate long term response of sulfonylurea and glucose control in children with diabetes due to mutations in ABCC8 that have been switched from insulin injections to sulfonylurea tablets.

Conditions

  • Permanent Neonatal Diabetes Mellitus

Interventions

DRUG

Sulfonylurea

See Arm description.

Sponsors & Collaborators

  • University of Bergen

    collaborator OTHER

  • University of Exeter

    collaborator OTHER

  • Royal Devon and Exeter NHS Foundation Trust

    collaborator OTHER

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Hôpital Necker-Enfants Malades

    collaborator OTHER

  • University of Rome Tor Vergata

    collaborator OTHER

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Pål Rasmus Njølstad, MD, PhD · Haukeland University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
9 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-15
Primary Completion
2020-02-29
Completion
2020-02-29

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02624830 on ClinicalTrials.gov